Interpretation of Chinese Expert Consensus on the Diagnosis and Management Strategy of Patients with Statin Intolerance: A guiding file for helping to lipid management for Chinese population  

作　　者：Jian-Jun LI 

机构地区：[1]Cardiometabolic Center,National Center for Cardiovascular Disease,Chinese Academy of Medical Science,Fuwai Hospital,Beijing,China

出　　处：《Journal of Geriatric Cardiology》2024年第7期713-715,共3页老年心脏病学杂志（英文版）

基　　金：supported by CAMS Innovation Fund for Medical Sciences(CIFMS,2021-I2M-C&TB-030).

摘　　要：It is well-known that elevated low-density lipoprotein cholesterol(LDL-C)is a causal risk factor for atheroscler-otic cardiovascular disease(ASCVD),statins are cornerstone drugs for the cause-based treatment of ASCVD,which has created a new era for ASCVD therapy.However,statin intolerance is not clinically uncommon,which there are several issues with confu-sion and misunderstandings.Hence,a file named Chinese Expert Consensus on the Diagnosis and Management Strategy of Pa-tients With Statin Intolerance,like a navigator,has recently been published written by a team of experts from the Cardiovascular Metabolic Medicine Professional Committee,Expert Committee of the National Center for Cardiovascular Diseases aiming to en-hance the standardized clinical application of statins and improve the prevention and clinical outcome.In this article,author briefly summarized the key points of above consensus in order to helping to comprehending the content of the consensus sugges-tions.

关 键 词：EXPERT STRATEGY CORNERS 

分 类 号：R972[医药卫生—药品]